The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
Authors
Keywords
-
Journal
Journal of Personalized Medicine
Volume 11, Issue 7, Pages 651
Publisher
MDPI AG
Online
2021-07-12
DOI
10.3390/jpm11070651
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LAG3’s Enigmatic Mechanism of Action
- (2021) Colin G. Graydon et al. Frontiers in Immunology
- Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma
- (2020) Minh Phuong Dong et al. Scientific Reports
- Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
- (2020) Zi Mei et al. International Journal of Oral Science
- Further clinical interpretation and implications of KEYNOTE-048 findings
- (2020) Petr Szturz et al. LANCET
- Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma
- (2020) Ilaria Grazia Zizzari et al. Cancers
- Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck
- (2019) Elie El Rassy et al. Future Oncology
- Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
- (2019) Solène-Florence Kammerer-Jacquet et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer
- (2019) Cinzia Solinas et al. Cancers
- The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions
- (2019) Joël Guigay et al. Frontiers in Oncology
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-γ in peripheral blood
- (2018) Na Li et al. Cancer Biomarkers
- sLAG-3 in non-small-cell lung cancer patients’ serum
- (2018) Yayi He et al. OncoTargets and Therapy
- Soluble immune checkpoints in cancer: production, function and biological significance
- (2018) Daqian Gu et al. Journal for ImmunoTherapy of Cancer
- PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
- (2017) Pedro N Aguiar et al. Immunotherapy
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
- (2017) Xinxin Zhu et al. Oncotarget
- RECIST 1.1—Update and clarification: From the RECIST committee
- (2016) Lawrence H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
- (2016) Wei-Wei Deng et al. OncoImmunology
- Immunology and Immunotherapy of Head and Neck Cancer
- (2015) Robert L. Ferris JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels
- (2014) Anna M. Leung et al. Frontiers in Oncology
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
- (2011) Yongjing Chen et al. CYTOKINE
- Cytokines in Cancer Immunotherapy
- (2011) Sylvia Lee et al. Cancers
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now